Integration of quality by design with artificial intelligence/machine learning technologies in pharmaceutical manufacturing: A comprehensive review
Review paper
DOI:
https://doi.org/10.5599/admet.3565Keywords:
Quality by testing, critical quality attributes, deep neural networks, process analytical technology, digital twins, continuous manufacturingAbstract
Background and purpose: Quality by design (QbD) has revolutionized pharmaceutical development by shifting from a conventional quality-by-testing approach to a science-based approach that incorporates quality into products and processes from inception. The integration of artificial intelligence (AI), machine learning (ML), automation, and digital technologies with QbD offers new opportunities to enhance process understanding, optimize critical quality attributes (CQAs) and support the Pharma 4.0 industry framework. Experimental approach: A systematic review of studies published between 2016 and 2025 was conducted to evaluate the application of supervised learning algorithms, deep neural networks, reinforcement learning, and digital twin technologies within QbD. Regulatory frameworks, including International Council for Harmonisation (ICH) quality guideline Q8 through Q14, the U.S. Food and Drug Administration’s Emerging Technology Program and the European Medicines Agency quality initiative, together with representative industrial case studies, were also examined. Key results: This review demonstrates that AI-driven QbD improves process understanding, CQA optimization, batch-to-batch consistency, process robustness, and real-time quality control. Further, advanced computational models enable predictive process monitoring, intelligent decision-making, and in silico experimentation, reducing manufacturing costs, development time and experimental burden. However, challenges related to data quality, model interpretability, validation, and regulatory harmonisation remain a critical barrier to widespread implementation. Conclusion: The convergence of AI, ML and QbD provides a robust framework for intelligent pharmaceutical manufacturing (PM). AI-enabled QbD supports the development of high-quality products through predictive, data-driven, and in silico approaches while accelerating development and improving manufacturing efficiency. These technologies offer a practical roadmap toward Pharma 4.0 and the future of digital PM.
Downloads
References
[1] Z. Zhu. Intelligent information management enables quality-by-design in pharmaceutical production. Scientific Reports 15 (2025) 44201. https://doi.org/10.1038/s41598-025-27879-w DOI: https://doi.org/10.1038/s41598-025-27879-w
[2] ICH Q8 Explained: A Guide to Pharmaceutical Development & QbD. https://intuitionlabs.ai/articles/ich-q8-pharmaceutical-development (Accessed June 16, 2026)
[3] ICH Q8 (R2) Pharmaceutical development - Scientific guidelin. https://www.ema.europa.eu/en/ich-q8-r2-pharmaceutical-development-scientific-guideline (Accessed August 14, 2026)
[4] J.G. Duarte, M.G. Duarte, A.P. Piedade, F. Mascarenhas-Melo. Rethinking Pharmaceutical Industry with Quality by Design: Application in Research, Development, Manufacturing, and Quality Assurance. The AAPS Journal 27 (2025) 96. https://doi.org/10.1208/s12248-025-01079-w DOI: https://doi.org/10.1208/s12248-025-01079-w
[5] N.K. Jain, N. Bajwa, Introduction to Quality by Design (QbD): From Theory to Practice, Springer, Singapore, Singapore, 2024, p. 493. https://doi.org/10.1007/978-981-99-8034-5 DOI: https://doi.org/10.1007/978-981-99-8034-5
[6] C. Sarkar, B. Das, V.S. Rawat, J.B. Wahlang, A. Nongpiur, I. Tiewsoh, N.M. Lyngdoh, D. Das, M. Bidarolli, H.T. Sony. Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. International Journal of Molecular Sciences 24 (2023) 2026. https://doi.org/10.3390/ijms24032026 DOI: https://doi.org/10.3390/ijms24032026
[7] B. Jadhav, H. Gangurde, K. Deshmukh, R. Dhakane, N. Dhole. Artificial Intelligence in the Pharmaceutical Industry: A Comprehensive Review. International Journal of Pharmaceutical Sciences 11 (2025) 1207-1220. https://doi.org/10.5281/zenodo.17557545
[8] V. Verma, D. Kumar. Artificial intelligence and machine learning in drug discovery: From lead discovery to clinical validation (2020-2025). Letters in Drug Design & Discovery 22 (2026) 100341. https://doi.org/10.1016/j.lddd.2026.100341 DOI: https://doi.org/10.1016/j.lddd.2026.100341
[9] O. Kahane, R. Mahajan, V. Patil. QBD 2.0: An Integrated Five-Pillar Based Conceptual Predictive Lifecycle Framework for Next-Generation Pharmaceutical Development. International Journal of Pharmaceutical Sciences 4 (2026) 1891-1905. https://doi.org/10.5281/zenodo.18301973
[10] Focus area of Regulatory Science Report. https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-advanced-manufacturing (Accessed June 16, 2026)
[11] Emerging Technology Program (ETP) │FDA. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/emerging-technology-program-etp (Accessed June 18, 2026)
[12] FDA AI Guidance 2026: Drug Manufacturing & Digital Health. https://intuitionlabs.ai/articles/fda-ai-guidance-2026-drug-manufacturing-digital-health (Accessed August 14, 2026)
[13] FRAME: Supporting Advanced Manufacturing Technologies. https://www.fda.gov/media/174249/download (Accessed June 16, 2026)
[14] ICH Q12 Technical and regulatory considerations for pharmaceutical product lifecycle management - Scientific guideline. https://www.ema.europa.eu/en/ich-q12-technical-regulatory-considerations-pharmaceutical-product-lifecycle-management-scientific-guideline (Accessed June 16, 2026).
[15] K. Huanbutta, K. Burapapadh, P. Kraisit, P. Sriamornsak, T. Ganokratanaa, K. Suwanpitak, T. Sangnim. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. European Journal of Pharmaceutical Sciences 203 (2024) 106938. https://doi.org/10.1016/j.ejps.2024.106938 DOI: https://doi.org/10.1016/j.ejps.2024.106938
[16] I. Walsh, M. Myint, T. Nguyen-Khuong, Y.S. Ho, S.K. Ng, M. Lakshmanan. Harnessing the potential of machine learning for advancing "Quality by Design" in biomanufacturing. Mabs 14 (2022) 2013593. https://doi.org/10.1080/19420862.2021.2013593 DOI: https://doi.org/10.1080/19420862.2021.2013593
[17] D.C. Psichogios, L.H. Ungar. A hybrid neural network‐first principles approach to process modeling. AIChE Journal 38 (1992) 1499-1511. https://doi.org/10.1002/aic.690381003 DOI: https://doi.org/10.1002/aic.690381003
[18] H. Askr, E. Elgeldawi, H. Aboul Ella, Y.A. Elshaier, M.M. Gomaa, A.E. Hassanien. Deep learning in drug discovery: an integrative review and future challenges. Artificial Intelligence Review 56 (2023) 5975-6037. https://doi.org/10.1007/s10462-022-10306-1 DOI: https://doi.org/10.1007/s10462-022-10306-1
[19] PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pat-framework-innovative-pharmaceutical-development-manufacturing-and-quality-assurance (Accessed June 18, 2026)
[20] A.K. Kausik, A.B. Rashid, R.F. Baki, M.M. Maktum. Machine learning algorithms for manufacturing quality assurance: A systematic review of performance metrics and applications. Array 26 (2025) 100393. https://doi.org/10.1016/j.array.2025.100393 DOI: https://doi.org/10.1016/j.array.2025.100393
[21] Real-Time Release Testing: The Next Leap in Pharmaceutical Manufacturing. https://www.pharmasalmanac.com/articles/real-time-release-testing-the-next-leap-in-pharmaceutical-manufacturing (Accessed June 18, 2026)
[22] R.A Lionberger, S.L. Lee, L. Lee, A. Raw, L.X. Yu. Quality by design: concepts for ANDAs. The AAPS journal 10 (2008) 268-76. https://doi.org/10.1208/s12248-008-9026-7 DOI: https://doi.org/10.1208/s12248-008-9026-7
[23] ICH Q11 Development and manufacture of drug substances (chemical entities and biotechnological/biological entities) - Scientific guideline, https://www.ema.europa.eu/en/ich-q11-development-manufacture-drug-substances-chemical-entities-biotechnological-biological-entities-scientific-guideline (Accessed June 18, 2026)
[24] Global Adoption Status and Implementation of ICH Guidelines Q12, Q2(R2), and Q14. https://ispe.org/pharmaceutical-engineering/ispeak/global-adoption-status-and-implementation-ich-guidelines-q12-q2r2 (Accessed June 18, 2026)
[25] Quality Target Product Profile (QTPP) in Pharmaceutical Development, https://pharmatopics.com/quality-target-product-profile-qtpp-in-pharmaceutical-development/ (Accessed June 18, 2026).
[26] L.X. Yu. Pharmaceutical quality by design: product and process development, understanding, and control. Pharmaceutical research 25 (2008) 781-91. https://doi.org/10.1007/s11095-007-9511-1 DOI: https://doi.org/10.1007/s11095-007-9511-1
[27] O.S. Satpute, M.S. Kirve, K.K. Shinde, Y.B. Tambade. Review On Quality by Design (Qbd) In Pharmaceutical Development. International Journal of Pharmaceutical Sciences 4 (2026) 4725-4735. https://doi.org/10.5281/zenodo.20751710
[28] Critical Quality Attribute (CQA) in 2026: Expert Guide to Ensure Drug Quality, https://pharmuni.com/2026/04/09/critical-quality-attribute-cqa-in-year-expert-guide-to-ensure-drug-quality/ (Accessed June 19, 2026).
[29] Critical Quality Attribute (CQA) in Pharmaceutical Development. https://www.m-pharmainfo.com/2025/05/critical-quality-attributes-cqas-in.html (Accessed June 19, 2026)
[30] Critical Quality Attributes (CQAs) in Biologics Manufacturing: Why They Matter. https://53biologics.com/cqa-in-biologics/ (Accessed June 19, 2026).
[31] D.H. Stamatis, Failure Mode and Effect Analysis: FMEA from Theory to Execution, ASQ Quality Press, Milwaukee, USA, 2003, p. 215. ISBN 9780873895989.
[32] Critical Process Parameters (CPPs) - Batch Control https://sgsystemsglobal.com/glossary/critical-process-parameters-cpps-batch-control/ (Accessed June 19, 2026)
[33] G. Cui, R. Wu, L. Cao, S. Abedin, K. Goel, S. Yoon, X. Wang. Optical Fiber pH and Dissolved Oxygen Sensors for Bioreactor Monitoring: A Review. Sensors (Basel) 26 (2026) 10. https://doi.org/10.3390/s26010010 DOI: https://doi.org/10.3390/s26010010
[34] S.C. Ferreira, R.E. Bruns, H.S. Ferreira, G.D. Matos, J.M. David, G.C. Brandão, E.P. da Silva, L.A. Portugal, P.S. Dos Reis, A.S. Souza, W.N. Dos Santos. Box-Behnken design: An alternative for the optimization of analytical methods. Analytica Chimica Acta 597 (2007) 179-186. https://doi.org/10.1016/j.aca.2007.07.011 DOI: https://doi.org/10.1016/j.aca.2007.07.011
[35] Quality by Design (QbD) in Pharma Explained: Ultimate Guide to Regulatory Implementation and Compliance. https://www.pharmaregulatory.in/quality-by-design-qbd-in-pharma-explained-ultimate-guide-to-regulatory-implementation-and-compliance/ (Accessed August 14, 2026)
[36] T.A. Little. Essentials in Establishing and Using Design Space. BioPharm International 26 (2013). https://www.biopharminternational.com/view/essentials-establishing-and-using-design-space
[37] L.L. Simon, H. Pataki, G. Marosi, F. Meemken, K. Hungerbühler, A. Baiker, S. Tummala, B. Glennon, M. Kuentz, G. Steele, H.J. Kramer. Assessment of recent process analytical technology (PAT) trends: a multiauthor review. Organic Process Research & Development 19 (2015) 3-62. https://doi.org/10.1021/op500261y DOI: https://doi.org/10.1021/op500261y
[38] H.M. Nguyen-Khac, F. Alyoussef, A. Bech, A. Barr, S. Sapsford, C. Gerada, A. Cairns. Advanced feedforward control techniques: Comprehensive review and a real-time industrial application. Annual Reviews in Control 61 (2026) 101044. https://doi.org/10.1016/j.arcontrol.2025.101044 DOI: https://doi.org/10.1016/j.arcontrol.2025.101044
[39] S. Garcı́a-Muñoz, J. Mercado. Optimal selection of raw materials for pharmaceutical drug product design and manufacture using mixed integer nonlinear programming and multivariate latent variable regression models. Industrial & Engineering Chemistry Research 52 (2013) 5934-5942. https://doi.org/10.1021/ie3031828 DOI: https://doi.org/10.1021/ie3031828
[40] QbD vs Traditional Stability Study Planning: A Comparative Approach, https://www.stabilitystudies.in/qbd-vs-traditional-stability-study-planning-a-comparative-approach/ (Accessed June 21, 2026)
[41] P.B. Aru, M.S. Gulhane, V.A. Katekar, S.P. Deshmukh. Quality by Design (QbD) in pharmaceutical development: A comprehensive review. GSC Biological and Pharmaceutical Sciences 26 (2024) 328-340. https://doi.org/10.30574/gscbps.2024.26.1.0019 DOI: https://doi.org/10.30574/gscbps.2024.26.1.0019
[42] K. Pramod, M.A. Tahir, N.A. Charoo, S.H. Ansari, J. Ali. Pharmaceutical product development: A quality by design approach. International Journal of Pharmaceutical Investigation 6 (2016) 129-138. https://doi.org/10.4103/2230-973X.187350 DOI: https://doi.org/10.4103/2230-973X.187350
[43] L.X. Yu, G. Amidon, M.A. Khan, S.W. Hoag, J. Polli, G.K. Raju, J. Woodcock. Understanding pharmaceutical quality by design. The AAPS Journal 16 (2014) 771-783. https://doi.org/10.1208/s12248-014-9598-3 DOI: https://doi.org/10.1208/s12248-014-9598-3
[44] L.K. Vora, A.D. Gholap, K. Jetha, R.R.S. Thakur, H.K. Solanki, V.P. Chavda. Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics 15 (2023) 1916. https://doi.org/10.3390/pharmaceutics15071916 DOI: https://doi.org/10.3390/pharmaceutics15071916
[45] S.K. Niazi. Regulatory Perspectives for AI/ML Implementation in Pharmaceutical GMP Environments. Pharmaceuticals 18 (2025) 901. https://doi.org/10.3390/ph18060901 DOI: https://doi.org/10.3390/ph18060901
[46] Guiding principles of good AI practice in drug development. https://www.fda.gov/about-fda/artificial-intelligence-drug-development/guiding-principles-good-ai-practice-drug-development (Accessed June 22, 2026)
[47] Transparency for Machine Learning-Enabled Medical Devices: Guiding Principles. https://www.fda.gov/medical-devices/software-medical-device-samd/transparency-machine-learning-enabled-medical-devices-guiding-principles (Accessed June 22, 2026)
[48] D. Deshmukh, S. Datkhile, O. Gosavi, K. Aher, K. Gaikwad, B. Gurav. Artificial Intelligence and Machine Learning in Pharmaceutical Quality Assurance. International Journal of Pharmaceutical Sciences 3 (2025) 771-786. https://doi.org/10.5281/zenodo.17067967
[49] W.S. Noble. What is a support vector machine? Nature Biotechnology 24 (2006) 1565-1567. https://doi.org/10.1038/nbt1206-1565 DOI: https://doi.org/10.1038/nbt1206-1565
[50] X. Dong, Z. Yu, W. Cao, Y. Shi, Q. Ma. A survey on ensemble learning. Frontiers of Computer Science 14 (2019) 241-258. https://doi.org/10.1007/s11704-019-8208-z DOI: https://doi.org/10.1007/s11704-019-8208-z
[51] Y. LeCun, Y. Bengio, G. Hinton. Deep learning. Nature 521 (2015) 436-444. https://doi.org/10.1038/nature14539 DOI: https://doi.org/10.1038/nature14539
[52] S. Hochreiter, J. Schmidhuber. Long Short-Term Memory. Neural computation 9 (1997) 1735-1780. https://doi.org/10.1162/neco.1997.9.8.1735 DOI: https://doi.org/10.1162/neco.1997.9.8.1735
[53] G. Pang, C. Shen, L. Cao, A. Van Den Hengel. Deep learning for anomaly detection. ACM Computing Surveys 54 (2021) 1-38. https://doi.org/10.1145/3439950 DOI: https://doi.org/10.1145/3439950
[54] R.S. Sutton, A.G. Barto, Reinforcement Learning: An Introduction, MIT Press, Cambridge, USA, 2018, p. 552. ISBN 9780262039246.
[55] Artificial intelligence - European Medicines Agency (EMA). https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/artificial-intelligence (Accessed June 24, 2026)
[56] A.M. Salih, Z. Raisi-Estabragh, I.B. Galazzo, P. Radeva, S.E. Petersen, K. Lekadir, G. Menegaz. A perspective on explainable artificial intelligence methods: SHAP and LIME. Advanced Intelligent Systems 7 (2024) 2400304. https://doi.org/10.1002/aisy.202400304 DOI: https://doi.org/10.1002/aisy.202400304
[57] Identifying CMAs and CPPs in QbD: Roles and Methodologies https://senpharma.vn/en/identifying-cmas-and-cpps-in-qbd-roles-and-method/ (Accessed June 24, 2026)
[58] L. Farah, J.M. Murris, I. Borget, A. Guilloux, N.M. Martelli, S.I. Katsahian. Assessment of performance, interpretability, and explainability in artificial intelligence-based health technologies: what healthcare stakeholders need to know. Mayo Clinic Proceedings: Digital Health 1 (2023) 120-138. https://doi.org/10.1016/j.mcpdig.2023.02.004 DOI: https://doi.org/10.1016/j.mcpdig.2023.02.004
[59] AI Algorithm Qualification: A Quality by Design Lens on Regulatory Readiness. https://ispe.org/pharmaceutical-engineering/ispeak/ai-algorithm-qualification-quality-design-lens-regulatory (Accessed June 24, 2026
[60] ICH Q8 R2: How to apply Quality by Design and win regulatory confidence. https://www.scilife.io/blog/ich-q8 (Accessed August 15, 2026)
[61] K. Odonnell, U. Kartoglu. QRM, Knowledge Management, and the Importance of ICH Q9(R1). Pharmaceutical Technology 48 (2024) 20-31. https://www.pharmtech.com/view/qrm-knowledge-management-and-the-importance-of-ich-q9-r1-
[62] Quality by Design (QbD) & PAT in Pharma Manufacturing. https://intuitionlabs.ai/articles/qbd-pat-pharma-manufacturing (Accessed June 25, 2026)
[63] Data Preprocessing in ML: Cleaning, Normalization, and Encoding https://www.sanfoundry.com/data-preprocessing-ml-cleaning-normalization-encoding/ (Accessed June 25, 2026)
[64] Z. Wu, C. Liang. A Review and Prospects of Manufacturing Process Knowledge Acquisition, Representation, and Application. Machines 12 (2024) 416. https://doi.org/10.3390/machines12060416 DOI: https://doi.org/10.3390/machines12060416
[65] M. Patel, A. Prajapati, S. Narkhede, S. Luhar, E. Patel. AI-Enable Quality by Design in Pharmaceutical Formulation. International Journal of Technology 15 (2025) 75-81. https://doi.org/10.52711/2231-3915.2025.00014 DOI: https://doi.org/10.52711/2231-3915.2025.00014
[66] G. Nakka, S. Gupta, K.K. Reddy. Artificial intelligence in pharmaceutical manufacturing: Applications, case studies, and GxP implementation considerations. Journal of Pharmaceutical Sciences 115 (2026) 104240. https://doi.org/10.1016/j.xphs.2026.104240 DOI: https://doi.org/10.1016/j.xphs.2026.104240
[67] Validation & Qualification Compliance in Pharmaceutical Manufacturing. https://www.pharma.tips/validation-qualification-compliance-in-pharmaceutical-manufacturing/ (Accessed June 25, 2026)
[68] H.B. Grangeia, C. Silva, S.P. Simoes, M.S. Reis. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. European Journal of Pharmaceutics and Biopharmaceutics 147 (2020) 19-37. https://doi.org/10.1016/j.ejpb.2019.12.007 DOI: https://doi.org/10.1016/j.ejpb.2019.12.007
[69] R. Abdulhussain, H. Muhamad, T. Fiza, S. Dereiah, N. Mawla, K. Patel, A. Adebisi, K. Asare-Addo. The integration of artificial intelligence through quality by digital design for sustainable pharmaceutical manufacturing. International Journal of Pharmaceutics 693 (2026) 126682. https://doi.org/10.1016/j.ijpharm.2026.126682 DOI: https://doi.org/10.1016/j.ijpharm.2026.126682
[70] S. Yang, X. Hu, J. Zhu, B. Zheng, W. Bi, X. Wang, J. Wu, Z. Mi, Y. Wu. Aspects and Implementation of Pharmaceutical Quality by Design from Conceptual Frameworks to Industrial Applications. Pharmaceutics 17 (2025) 623. https://doi.org/10.3390/pharmaceutics17050623 DOI: https://doi.org/10.3390/pharmaceutics17050623
[71] S. Kant, Deepika, S. Roy. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences 1 (2025) 7. https://doi.org/10.1007/s44395-025-00007-3 DOI: https://doi.org/10.1007/s44395-025-00007-3
[72] J. Vamathevan, D. Clark, P. Czodrowski, I. Dunham, E. Ferran, G. Lee, B. Li, A. Madabhushi, P. Shah, M. Spitzer, S. Zhao. Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery 18 (2019) 463-477. https://doi.org/10.1038/s41573-019-0024-5 DOI: https://doi.org/10.1038/s41573-019-0024-5
[73] N. Jain, S. Kaul, Triveni, A. Kaith, A. Sinha, T. Mathur, M. Pandey, U. Nagaich, QbD and artificial intelligence in nanoparticulate drug delivery systems: recent advances, in Volume 2 Computational Drug Delivery: Molecular Simulation for Pharmaceutical Formulation, P.A. Chawla, D. Singh, K. Dua, M. Dhanasekaran, V. Chawla, Ed(s)., De Gruyter, Berlin, Germany, 2024, p. 163-182. https://doi.org/10.1515/9783111208671-008 DOI: https://doi.org/10.1515/9783111208671-008
[74] A.S. Rathore, H. Winkle. Quality by design for biopharmaceuticals. Nature Biotechnology 27 (2009) 26-34. https://doi.org/10.1038/nbt0109-26 DOI: https://doi.org/10.1038/nbt0109-26
[75] K.R. Sharma, K.V. Sharma, Z. Khan, D. Jindal, V. Garg. Artificial Intelligence-Assisted Formulation Development in Pharmaceutics: Current Applications, Challenges and Future Perspectives. International Journal of Pharmaceutical Sciences 4 (2026) 193-198. https://doi.org/10.5281/zenodo.21113149
[76] A.M. Dean, D. Voss, D. Draguljic, Design and Analysis of Experiments, Springer International Publishing, Cham, Switzerland, 2017, p. 840. https://doi.org/10.1007/978-3-319-52250-0 DOI: https://doi.org/10.1007/978-3-319-52250-0
[77] M. Yafout, A. Ousaid, J. Akrim, Y. Khayati. Integrating artificial intelligence with process analytical technology for real time pharmaceutical process monitoring: a comprehensive review. Asian Journal of Research in Medical and Pharmaceutical Sciences 14 (2025) 139-151. https://doi.org/10.9734/ajrimps/2025/v14i3326 DOI: https://doi.org/10.9734/ajrimps/2025/v14i3326
[78] ICH Q10 Pharmaceutical quality system - Scientific guideline. https://www.ema.europa.eu/en/ich-q10-pharmaceutical-quality-system-scientific-guideline (Accessed June 25, 2026).
[79] Quality Control in Manufacturing: Overview and Best Practices. https://www.6sigma.us/manufacturing/quality-control-in-manufacturing/ (Accessed June 25, 2026)
[80] I. Aifuwa. PAT strategies and applications for cell therapy processing. Current Opinion in Biomedical Engineering 24 (2022) 100405. https://doi.org/10.1016/j.cobme.2022.100405 DOI: https://doi.org/10.1016/j.cobme.2022.100405
[81] R.W. Bondi Jr., J.K. Drennen III, Quality by Design and the Importance of PAT in QbD, in Separation Science and Technology, S. Ahuja, S. Scypinski, Ed(s)., Academic Press, Cambridge, USA, 2011, p. 195-224. https://doi.org/10.1016/B978-0-12-375680-0.00005-X DOI: https://doi.org/10.1016/B978-0-12-375680-0.00005-X
[82] E.T. Skibsted, J.A. Westerhuis, A.K. Smilde, D.T. Witte. Examples of NIR based real time release in tablet manufacturing. Journal of Pharmaceutical and Biomedical Analysis 43 (2007) 1297-1305. https://doi.org/10.1016/j.jpba.2006.10.037 DOI: https://doi.org/10.1016/j.jpba.2006.10.037
[83] M. Blanco, M. Alcalá. Content uniformity and tablet hardness testing of intact pharmaceutical tablets by near infrared spectroscopy: a contribution to process analytical technologies. Analytica Chimica Acta 557 (2006) 353-359. https://doi.org/10.1016/j.aca.2005.09.070 DOI: https://doi.org/10.1016/j.aca.2005.09.070
[84] A. Abdullahi, T. Korumilli, S. Subburaj, S.J. Abubakar, Spectroscopic Techniques (NIR, FTIR, and Raman) for Nutritional Profiling, in Novel Food Analysis: Techniques and Applications, T. Sarkar, Ed(s)., Springer US, New York, USA, 2025, p. 181-199. https://doi.org/10.1007/978-1-0716-4787-5_9 DOI: https://doi.org/10.1007/978-1-0716-4787-5_9
[85] G. Thakur, A.S. Rathore. Near Infrared Spectroscopy as a Versatile PAT Tool for Continuous Downstream Bioprocessing. Pharmaceutical Technology 45 (2021) 32-40. https://www.pharmtech.com/view/near-infrared-spectroscopy-as-a-versatile-pat-tool-for-continuous-downstream-bioprocessing
[86] K.A. Esmonde-White, M. Cuellar, C. Uerpmann, B. Lenain, I.R. Lewis. Raman spectroscopy as a process analytical technology for pharmaceutical manufacturing and bioprocessing. Analytical and Bioanalytical Chemistry 409 (2017) 637-649. https://doi.org/10.1007/s00216-016-9824-1 DOI: https://doi.org/10.1007/s00216-016-9824-1
[87] Principles of Raman spectroscopy | Endress+Hauser. https://www.casc.endress.com/en/support-overview/learning-center/raman-spectroscopy-measuring-principle (Accessed June 25, 2026)
[88] Development and Submission of Near Infrared Analytical Procedures. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-submission-near-infrared-analytical-procedures (Accessed June 29, 2026)
[89] T.R.M. De Beer, C. Bodson, B. Dejaegher, B. Walczak, P. Vercruysse, A. Burggraeve, A. Lemos, L. Delattre, Y. Vander Heyden, J.P. Remon, C. Vervaet, W.R.G. Baeyens. Raman spectroscopy as a process analytical technology (PAT) tool for the in-line monitoring and understanding of a powder blending process. Journal of Pharmaceutical and Biomedical Analysis 48 (2008) 772-779. https://doi.org/10.1016/j.jpba.2008.07.023 DOI: https://doi.org/10.1016/j.jpba.2008.07.023
[90] Y. Roggo, P. Chalus, L. Maurer, C. Lema-Martinez, A. Edmond, N. Jent. A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies. Journal of Pharmaceutical and Biomedical Analysis 44 (2007) 683-700. https://doi.org/10.1016/j.jpba.2007.03.023 DOI: https://doi.org/10.1016/j.jpba.2007.03.023
[91] J.A. Zeitler, Y.C. Shen, Industrial applications of terahertz imaging, in Terahertz Spectroscopy and Imaging, K.E. Peiponen, J.A. Zeitler, M. Kuwata-Gonokami, Ed(s)., Springer Berlin Heidelberg, Berlin, Germany, 2012, p. 451-489. https://doi.org/10.1007/978-3-642-29564-5_18 DOI: https://doi.org/10.1007/978-3-642-29564-5_18
[92] R.K. May, M.J. Evans, S. Zhong, I. Warr, L.F. Gladden, Y. Shen, J.A. Zeitler. Terahertz in-line sensor for direct coating thickness measurement of individual tablets during film coating in real-time. Journal of Pharmaceutical Sciences 100 (2011) 1535-1544. https://doi.org/10.1002/jps.22359 DOI: https://doi.org/10.1002/jps.22359
[93] J. Rantanen, J. Khinast. The future of pharmaceutical manufacturing sciences. Journal of Pharmaceutical Sciences 104 (2015) 3612-3638. https://doi.org/10.1002/jps.24594 DOI: https://doi.org/10.1002/jps.24594
[94] G. Gerzon, Y. Sheng, M. Kirkitadze. Process analytical technologies-advances in bioprocess integration and future perspectives. Journal of Pharmaceutical and Biomedical Analysis 207 (2022) 114379. https://doi.org/10.1016/j.jpba.2021.114379 DOI: https://doi.org/10.1016/j.jpba.2021.114379
[95] PAT Sensors for Real-Time Reaction Monitoring in Pharma. https://intuitionlabs.ai/articles/pat-sensors-pharma-manufacturing (Accessed August 15, 2026)
[96] L.S. Bhimrao, S. Kumar, A.K. Agrawal, T. De Beer, A. Kumar, D. Kumar. Continuous Manufacturing in pharmaceuticals: an integrated approach with NIR and Raman as PAT tools. International Journal of Pharmaceutics 689 (2026) 126478. https://doi.org/10.1016/j.ijpharm.2025.126478 DOI: https://doi.org/10.1016/j.ijpharm.2025.126478
[97] Multivariate Data Analysis Software | Sartorius. https://www.sartorius.com/en/products/process-analytical-technology/data-analytics-software/mvda-software (Accessed June 29, 2026)
[98] C. Beckett, L. Eriksson, E. Johansson, C. Wikström, Multivariate data analysis (MVDA), in Pharmaceutical quality by design: A practical approach, W.S. Schlindwein, M. Gibson, Ed(s)., John Wiley & Sons Ltd, Chichester, UK, 2018, p. 201-225. https://doi.org/10.1002/9781118895238.ch8 DOI: https://doi.org/10.1002/9781118895238.ch8
[99] M. Shaikh, O. Rankhamb, S. Kamble, P. Chavan, O.G. Bhusnure. Digital Transformation of Pharmaceutical Quality Assurance through Industry 4.0: A narrative review. International Journal of Pharmaceutical Sciences 4 (2026) 4957-4975. https://doi.org/10.5281/zenodo.20758676
[100] T. Manzano, W. Whitford. Artificial Intelligence Empowering Process Analytical Technology and Continued Process Verification in Biotechnology. GEN Biotechnology 4 (2025) 23-28. https://doi.org/10.1089/genbio.2024.0041 DOI: https://doi.org/10.1089/genbio.2024.0041
[101] M. Garg, S. Singhal, Regulatory and Safety Aspects of Nanomedicine: Current Perspective in Managing Nanotoxicity, in Multifunctional Nano pharmaceuticals for Biomedical Applications, S.K. Kashaw, A.K. Iyer, R.K. Tekade, Rakesh K. Tekade S. Soni, Ed(s)., Academic Press, Cambridge, USA, 2027, p. 413-436. https://doi.org/10.1016/B978-0-443-44119-6.00013-6 DOI: https://doi.org/10.1016/B978-0-443-44119-6.00013-6
[102] D. Patel, S. Luhar, S. Narkhede. Integrating Artificial Intelligence (Ai) & Machine Learning (Ml) For Predictive Quality Control. International Journal of Pharmaceutical Sciences 4 (2026) 1818-1824. https://doi.org/10.5281/zenodo.19064684
[103] M.S. Chowdhury. Comparison of accuracy and reliability of random forest, support vector machine, artificial neural network and maximum likelihood method in land use/cover classification of urban setting. Environmental Challenges 14 (2024) 100800. https://doi.org/10.1016/j.envc.2023.100800 DOI: https://doi.org/10.1016/j.envc.2023.100800
[104] O. Péterfi, B. Kovács, T. Casian, E.O. Tőkés, É.K. Kelemen, K. Zöldi, Z.K. Nagy, B. Nagy. Comparison of surrogate models in tablet dissolution prediction: addressing the limitations of F₂ and introducing sum of ranking differences for model evaluation. The AAPS Journal 27 (2025) 118. https://doi.org/10.1208/s12248-025-01100-2 DOI: https://doi.org/10.1208/s12248-025-01100-2
[105] ICH Q12: Implementation Considerations for FDA-Regulated Products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ich-q12-implementation-considerations-fda-regulated-products (Accessed June 29, 2026)
[106] AI-Enabled Digital Twins in Biopharmaceutical Manufacturing. https://www.bioprocessintl.com/information-technology/ai-enabled-digital-twins-in-biopharmaceutical-manufacturing (Accessed June 29, 2026)
[107] P. Sharma, W.T. Chung, B. Akoush, M. Ihme. A Review of Physics-Informed Machine Learning in Fluid Mechanics. Energies 16 (2023) 2343. https://doi.org/10.3390/en16052343 DOI: https://doi.org/10.3390/en16052343
[108] Q. Feng, S. Daulton, B. Letham, M. Balandat, E. Bakshy, 31st ACM SIGKDD Conference on Knowledge Discovery and Data Mining, Experimenting, Fast and Slow: Bayesian Optimization of Long-term Outcomes with Online Experiments, Toronto, Canada, 2025, p. 2235-2246. https://doi.org/10.1145/3690624.3709419 DOI: https://doi.org/10.1145/3690624.3709419
[109] W. Ling, Enterprise digital transformation: An analysis of value creation from an operational perspective, Singapore Management University, Singapore, 2026, p. 1-116. https://ink.library.smu.edu.sg/etd_coll/850
[110] N. Nicolaï, I. Nopens, M. Verstraeten, T. De Beer, Process control levels for continuous pharmaceutical tablet manufacturing, in Chemical Engineering in the Pharmaceutical Industry, M.T. am Ende, D.J. am Ende, Ed(s)., John Wiley & Sons, Inc., Hoboken, USA, 2019, p. 561-584. https://doi.org/10.1002/9781119600800.ch73 DOI: https://doi.org/10.1002/9781119600800.ch73
[111] S.K. Niazi. Continuous manufacturing of recombinant drugs: comprehensive analysis of cost reduction strategies, regulatory pathways, and global implementation. Pharmaceuticals 18 (2025) 1157. https://doi.org/10.3390/ph18081157 DOI: https://doi.org/10.3390/ph18081157
[112] B. Partopour, D. Pollard. Advancing biopharmaceutical manufacturing: economic and sustainability assessment of end-to-end continuous production of monoclonal antibodies. Trends in Biotechnology 43 (2025) 462-475. https://doi.org/10.1016/j.tibtech.2024.10.007 DOI: https://doi.org/10.1016/j.tibtech.2024.10.007
[113] M. Deebes, M. Mahfouf, C. Omar, S. Islam, B. Morgan. A plant wide modelling framework for the multistage processes of the continuous manufacturing of pharmaceutical tablets. Journal of Pharmaceutical Innovation 20 (2025) 115. https://doi.org/10.1007/s12247-025-10017-4 DOI: https://doi.org/10.1007/s12247-025-10017-4
[114] S.L. Cantor, S.W. Hoag, C.D. Ellison, M.A. Khan, R.C. Lyon. NIR Spectroscopy Applications in the Development of a Compacted Multiparticulate System for Modified Release. AAPS PharmSciTech 12 (2021) 262-278. https://doi.org/10.1208/s12249-010-9580-z DOI: https://doi.org/10.1208/s12249-010-9580-z
[115] S. Agatonovic-Kustrin, R. Beresford. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research. Journal of Pharmaceutical and Biomedical Analysis 22 (2000) 717-727. https://doi.org/10.1016/S0731-7085(99)00272-1 DOI: https://doi.org/10.1016/S0731-7085(99)00272-1
[116] A.S. Rathore, G. Thakur, S. Nikita, S. Banerjee, Control of continuous manufacturing processes for production of monoclonal antibodies, in Process Control, Intensification, and Digitalisation in Continuous Biomanufacturing, G. Subramanian, Ed(s)., John Wiley & Sons, Ltd., Chichester, UK, 2022, p. 39-74. https://doi.org/10.1002/9783527827343.ch2 DOI: https://doi.org/10.1002/9783527827343.ch2
[117] K.A. Pathak, P. Kafle, A. Vikram. Deep learning-based defect detection in film-coated tablets using a convolutional neural network. International Journal of Pharmaceutics 671 (2025) 125220. https://doi.org/10.1016/j.ijpharm.2025.125220 DOI: https://doi.org/10.1016/j.ijpharm.2025.125220
[118] D.C. Higgins. OnRAMP for regulating AI in medical products. Advanced Intelligent Systems 3 (2020) 2100042. https://doi.org/10.1002/aisy.202100042 DOI: https://doi.org/10.1002/aisy.202100042
[119] CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) Initiative. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cders-framework-regulatory-advanced-manufacturing-evaluation-frame-initiative (Accessed June 30, 2026)
[120] M. Veale, F. Zuiderveen Borgesius. Demystifying the Draft EU Artificial Intelligence Act — Analysing the good, the bad, and the unclear elements of the proposed approach. Computer Law Review International 22 (2021) 97-112. https://doi.org/10.9785/cri-2021-220402 DOI: https://doi.org/10.9785/cri-2021-220402
[121] Ethics and governance of artificial intelligence for health: Guidance on large multi-modal models, https://www.who.int/publications/i/item/9789240084759 (Accessed June 30, 2026).
[122] Artificial Intelligence in Drug Manufacturing. https://www.fda.gov/media/165743/download (Accessed June 30, 2026)
[123] Artificial intelligence workplan to guide use of AI in medicines regulation. https://www.ema.europa.eu/en/news/artificial-intelligence-workplan-guide-use-ai-medicines-regulation (Accessed June 30, 2026)
[124] Regulation (EU) 2024/1689 of the European Parliament and of the Council. https://eur-lex.europa.eu/legal-content/EN/LSU/?uri=CELEX%3A32024R1689 (Accessed June 30, 2026).
[125] Reflection paper on the use of artificial intelligence in the lifecycle of medicines. https://www.ema.europa.eu/en/news/reflection-paper-use-artificial-intelligence-lifecycle-medicines (Accessed June 30, 2026)
[126] Considerations for the Use of Artificial Intelligence. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological (Accessed June 30, 2026)
[127] Stakeholders’ Consultation on EudraLex Volume 4 - Good Manufacturing Practice Guidelines: Chapter 4, Annex 11 and New Annex 22, https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-4-good-manufacturing-practice-guidelines-chapter-4-annex_en (Accessed June 30, 2026)
[128] H. Wu. Integration of PAT and Data Systems for Manufacturing Process Control and Quality Improvement: A Brief Review of Past Developments, Current Status, and Certain Future Considerations. American Pharmaceutical Review (2020). https://www.americanpharmaceuticalreview.com/Featured-Articles/569122-Integration-of-PAT-and-Data-Systems-for-Manufacturing-Process-Control-and-Quality-Improvement-A-Brief-Review-of-Past-Developments-Current-Status-and-Certain-Future-Considerations/
[129] L. Burroughs, M. Roy, S. Bhorkade, S. Badole, P.K. Pandey, A. Abhang, D.J. Burgess, Manufacturing of complex pharmaceuticals, in Harnessing Endogenous Mechanisms for Targeted Drug Delivery, A.A. D’Souza, L.S. Milane, M.M. Amiji, Ed(s)., Academic Press, Cambridge, USA, 2026, p. 1071-1129. https://www.sciencedirect.com/science/chapter/edited-volume/abs/pii/B978044327429900030X
[130] J. Pinto, J.R.C. Ramos, R.S. Costa, S. Rossell, P. Dumas, R. Oliveira. Hybrid deep modeling of a CHO-K1 fed-batch process: combining first-principles with deep neural networks. Frontiers in Bioengineering and Biotechnology 11 (2023) 1237963. https://doi.org/10.3389/fbioe.2023.1237963 DOI: https://doi.org/10.3389/fbioe.2023.1237963
[131] C. Rudin, J. Radin. Why are we using black box models in AI when we don’t need to? A lesson from an explainable AI competition. Harvard Data Science Review 1 (2019). https://doi.org/10.1162/99608f92.5a8a3a3d DOI: https://doi.org/10.1162/99608f92.5a8a3a3d
[132] S. Pasas-Farmer, R. Jain. From discovery to delivery: Governance of AI in the pharmaceutical industry. Green Analytical Chemistry 13 (2025) 100268. https://doi.org/10.1016/j.greeac.2025.100268 DOI: https://doi.org/10.1016/j.greeac.2025.100268
[133] F. Michelotto, L.A. Joia. Organizational Digital Transformation Readiness: An Exploratory Investigation. Journal of Theoretical and Applied Electronic Commerce Research 19 (2024) 3283-3304. https://doi.org/10.3390/jtaer19040159 DOI: https://doi.org/10.3390/jtaer19040159
[134] A Skill Management Framework for a Pharma 4.0™ Workforce. https://ispe.org/pharmaceutical-engineering/march-april-2025/skill-management-framework-pharma-40tm-workforce (Accessed June 30, 2026)
[135] Guide for Implementing an AI Governance Framework | IBM. https://www.ibm.com/think/insights/ai-governance-implementation (Accessed June 30, 2026)
[136] A. Rasheed, O. San, T. Kvamsdal. Digital twin: Values, challenges and enablers from a modeling perspective. IEEE Access 8 (2020) 21980-22012. https://doi.org/10.1109/ACCESS.2020.2970143 DOI: https://doi.org/10.1109/ACCESS.2020.2970143
[137] N. Rieke, J. Hancox, W. Li, F. Milletari, H.R. Roth, S. Albarqouni, S. Bakas, M.N. Galtier, B.A. Landman, K. Maier-Hein, S. Ourselin. The future of digital health with federated learning. NPJ Digital Medicine 3 (2020) 119. https://doi.org/10.1038/s41746-020-00323-1 DOI: https://doi.org/10.1038/s41746-020-00323-1
[138] A. Chase, A. Most, S. Xu, E. Barreto, B. Murray, K. Henry, S. Smith, T. Hedrick, X. Chen, S. Li, T. Liu, A. Sikora. Large language models management of complex medication regimens: a case-based evaluation. Frontiers in Pharmacology 16 (2025) 1514445. https://doi.org/10.3389/fphar.2025.1514445 DOI: https://doi.org/10.3389/fphar.2025.1514445
[139] D.U. Kapoor, A. Pareek, P. Uniyal, B.G. Prajapati, K. Thanawuth, P. Sriamornsak. Innovative applications of 3D printing in personalized medicine and complex drug delivery systems. iScience 28 (2025) 113505. https://doi.org/10.1016/j.isci.2025.113505 DOI: https://doi.org/10.1016/j.isci.2025.113505
[140] A.A. Alemie, E.A. Siraj, A.T. Yayehrad, C. Tafere, T.A. Tessema, A. Belete. Continuous pharmaceutical manufacturing and its contemporary regulatory insights. Discover Applied Sciences 7 (2025) 1057. https://doi.org/10.1007/s42452-025-07712-9 DOI: https://doi.org/10.1007/s42452-025-07712-9
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Sumit Ghosal, Niranjan Panda, Bikash Ranjan Jena, Madhusudan Maity, Sankhadip Bose, Rabinarayan Parhi
This work is licensed under a Creative Commons Attribution 4.0 International License.
